RVAC Medicines has received approval from the Health Sciences Authority (HSA) to commence the Phase IB clinical trial of three Covid-19 mRNA vaccine candidates in Singapore.
The trial has been designed for evaluating the immunogenicity and safety of the company’s three Covid-19 vaccine candidates.
The vaccine candidates include one against the Omicron strain, a bivalent vaccine candidate with both ancestral and Omicron strain components, and one against the ancestral strain.
RVAC Medicines CEO Dr. Sean Fu said: “The initiation of Singapore clinical studies is an important milestone in the development our Covid-19 vaccine candidates.
“It is also a strong validation of RVAC’s mRNA platform, which will further accelerate the advancement of future pipeline projects.”
Scheduled to begin this month, the Phase IB clinical trial will be conducted in collaboration with the National Centre for Infectious Diseases (NCID) of Singapore.
NCID Singapore Infectious Disease Clinical Research Network head Barnaby Young said: “I am delighted that our team at NCID is working with RVAC to develop a bivalent Covid-19 vaccine in Singapore.
“This vaccine has the potential to enhance protection against SARS-CoV-2 and emerging variants, keeping Singapore safe and resilient against future waves of infection.”
RVAC Medicines stated that the Phase IB clinical trial marks its second clinical trial.
The first trial, an open-label, dose-escalation Phase I trial, commenced in Australia in September last year.
It was designed for assessing the immunogenicity, tolerability, and safety of RVM-V001, an mRNA-based Covid-19 vaccine candidate, given as a single intramuscular injection in nearly 54 healthy adults.
This Phase I trial is part of a series of clinical trials that are designed to assess RVAC Medicines’ portfolio of Covid-19 vaccine candidates.
Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.